Related Experiment Videos
[Gene therapy of heart transplantation]
1Division de cardiologie, CHUV, Lausanne. giuseppe.vassalli@chuv.hospvd.ch
Abstract:
Somatic gene therapy involves the delivery and expression of a protective gene into a somatic organ. Cardiovascular gene therapy currently includes more than twenty clinical trials carried out worldwide. These trials evaluate gene delivery of vascular growth factors to the ischemic heart and legs in patients with coronary and peripheral artery disease, respectively. In contrast, no clinical trials have been carried out in gene therapy of heart transplantation. However, there is increasing experimental evidence for a therapeutic potential of this approach. Using a rat model of heart transplantation, we have shown that gene delivery of an inhibitor of interleukine-1, a pro-inflammatory molecule involved in allograft rejection, results in prolonged allograft survival. Another experimental study (5) has shown that gene transfer of a chimeric molecule comprising the cytotoxic T lymphocytic antigen-4 fused to an immunoglobulin (CTLA-4 Ig), which acts as a suppressor of T lymphocyte co-stimulation, induces an immune tolerance that is selective for the allograft. The recent development of gene transfer vectors that are capable of expressing a transgene for extended periods of time and in a regulatable manner represents an important step towards clinical applications in gene therapy of heart transplantation.
Insights
Somatic gene therapy shows promise for heart transplantation by delivering protective genes to prevent immune rejection. Experimental studies demonstrate prolonged allograft survival using gene therapy targeting inflammatory molecules and T cell responses.
Area of Science:
- * Cardiovascular research
- * Gene therapy applications
- * Transplantation immunology
Context:
- * Cardiovascular gene therapy has over twenty clinical trials globally, focusing on ischemic heart and leg diseases.
- * Heart transplantation lacks clinical gene therapy trials, despite growing experimental evidence.
- * Allograft rejection is a major challenge in heart transplantation.
Purpose:
- * To explore the therapeutic potential of somatic gene therapy in heart transplantation.
- * To investigate methods for prolonging allograft survival in heart transplant recipients.
- * To evaluate the efficacy of gene delivery targeting pro-inflammatory molecules and immune responses.
Summary:
- * Gene delivery of an interleukin-1 inhibitor prolonged allograft survival in a rat heart transplantation model.
- * Gene transfer of CTLA-4 Ig induced immune tolerance selective for the allograft.
- * Advanced gene transfer vectors enable sustained and regulated transgene expression, crucial for clinical application.
Impact:
- * Findings support the potential of gene therapy to improve outcomes in heart transplantation.
- * This research paves the way for future clinical trials in heart transplant gene therapy.
- * Development of novel therapeutic strategies for preventing allograft rejection.